Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Nauka-Svyaz reported for 9 months of 2023 by RAS

10/31/23 NSVZ

Rusal reported for 9 months of 2023 by RAS

10/31/23 RUAL

TNS Energy Kuban reported for 9 months of 2023 by RAS

10/31/23 KBSB

Permenergosbyt reported for 9 months of 2023 by RAS

10/31/23 PMSB

Amgen reported for 9 months of 2023

10/31/23 AMGN

Pfizer reported for 9 months of 2023

10/31/23 PFE

Caterpillar reported for 9 months of 2023

10/31/23 CAT

UTair reported for 9 months of 2023 by RAS

10/31/23 UTAR

Yandex launched a new method of passwordless authorization

10/31/23 YNDX

Rosseti Volga reported for 9 months of 2023 by RAS

10/31/23 MRKV